BELIEVER: Blister Eradication Looking at Impact of Experimental Versus Established Regimens

Sponsor
Stanford University (Other)
Overall Status
Recruiting
CT.gov ID
NCT03835806
Collaborator
(none)
130
3
2
40.1
43.3
1.1

Study Details

Study Description

Brief Summary

The specific aim of this study is to evaluate whether RockTape has similar efficacy to Elastikon in the treatment of foot blisters in ultramarathon runners. Elastikon with paper tape and spray adhesive is a well-accepted means of blister treatment and has been used by medical staff at over 50 multi-stage ultramarathons around the world. RockTape is another commercially available product that has also been used by runners successfully to treat foot blisters. RockTape's adhesive qualities have a potential advantage over Elastikon, in that it does not require an additional adhesive substituting a level of complexity, weight, and cost for foot care. There have been no studies examining the efficacy of either agent for blister treatment.

This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape, spray adhesive and then Elastikon to percutaneous drainage, paper tape and RockTape.

Condition or Disease Intervention/Treatment Phase
  • Other: Elastikon
  • Other: Rocktape
N/A

Detailed Description

Friction foot blisters are one of the most common injuries encountered by hikers and runners(1) with incidence as high as 39% in marathoners(2). In adventure races it is the most commonly reported injury(3) and in expedition length ultramarathons, blisters account for nearly 74% of medical visits(4). While most blisters are of minor medical significance, they can impair concentration, decrease athletic performance, and can be potentially debilitating.

The specific aim of this study is to evaluate whether RockTape has similar efficacy to Elastikon in the treatment of foot blisters in ultramarathon runners. Elastikon with paper tape and spray adhesive is a well-accepted means of blister treatment and has been used by medical staff at over 50 multi-stage ultramarathons around the world. RockTape is another commercially available product that has also been used by runners successfully to treat foot blisters. RockTape's adhesive qualities have a potential advantage over Elastikon, in that it does not require an additional adhesive substituting a level of complexity, weight, and cost for foot care. There have been no studies examining the efficacy of either agent for blister treatment.

This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape, spray adhesive and then Elastikon to percutaneous drainage, paper tape and RockTape.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
130 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This is a randomized control trial looking at a novel blister treatment intervention versus a traditional model.This is a randomized control trial looking at a novel blister treatment intervention versus a traditional model.
Masking:
None (Open Label)
Masking Description:
The treatments are visually dissimilar, therefore blinding for the investigator and subject is not possible.
Primary Purpose:
Treatment
Official Title:
Blister Eradication Looking at Impact of Experimental Versus Established Regimens
Actual Study Start Date :
Apr 27, 2019
Anticipated Primary Completion Date :
Aug 31, 2022
Anticipated Study Completion Date :
Aug 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Elastikon - traditional

The participant will be randomized to a treatment arm according to their racing bib number. Even bib numbers will be in the Elastikon treatment arm. The researcher will evaluate the blister and treat according to treatment arm with the following blister treatment device intervention: the blister will be prepped per routine, drained, covered with paper tape, sprayed with adhesive spray and then covered with Elastikon.

Other: Elastikon
This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape, spray adhesive and then Elastikon which is our traditional blister treatment approach.

Experimental: Rocktape - novel

The participant will be randomized to a treatment arm according to their racing bib number. Odd bib numbers will be in the Rocktape treatment arm. The researcher will evaluate the blister and treat according to treatment arm with the following blister treatment device intervention: the blister will be prepped per routine, drained, covered with paper tape and then covered with Rocktape

Other: Rocktape
This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape and then Rocktape which is our novel blister treatment approach.

Outcome Measures

Primary Outcome Measures

  1. Treatment success [Data will be collected during the 1 week ultramarathon in austere conditions until study completion, usually 3-5 days. This will be conducted over 3 separate races.]

    The subject's involvement in the study will end in one of the following situations and the researcher will fill out the appropriate data sheet at the time of the subject's departure from the study. The blister treatment is a success as defined by: the blister treatment falls off and the subject has no pain and no blister reoccurrence the blister treatment is removed by the subject and does not need to be replaced because the there is no pain or blister present the blister treatment stays on for the length of the study needing no intervention The blister treatment is a failure as defined by: if the blister re-occurs if the treated area has pain to the point that the blister treatment must be removed to evaluate if the subject removes the blister treatment and needs to be retreated. The race has come to completion The subject withdraws from the race or the study.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • The study enrollment period will run for approximately 7 days over 3 weeks throughout 2019 at Racing the Planet races in Namibia, Mongolia and Chile. All racers are potential subjects.

Subjects will be enrolled when they present to the medical tent for the treatment of their first painful blister. The subject will be evaluated for exclusion criteria and the subject will be asked to select the most painful blister to be included in the study. All other blisters may be treated through traditional means and are not included in the study.

Exclusion Criteria:
  • Blister exclusion criteria:
  1. Toe blisters will be excluded because they are treated with paper tape only to avoid friction against neighboring toes and further blister formation.

  2. Only intact blisters are included in this study as de-roofed blisters are treated differently.

  3. Hemorrhagic blisters are excluded as they are often not amenable to percutaneous drainage given the increased risk in infection.

If the most painful blister is a toe blister or a hemorrhagic blister, then the second most painful blister will be selected. If there is no second blister, the subject cannot be enrolled at this time.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Racing the Planet San Pedro de Atacama Chile
2 Racing the Planet Ulaan Baatar Mongolia
3 Namib Desert Windhoek Namibia

Sponsors and Collaborators

  • Stanford University

Investigators

  • Principal Investigator: Patrick B Burns, MD, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Patrick B Burns, Clinical Assistant Professor, Stanford University
ClinicalTrials.gov Identifier:
NCT03835806
Other Study ID Numbers:
  • IRB-49612
First Posted:
Feb 11, 2019
Last Update Posted:
Jun 25, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 25, 2021